Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX restores activity in the intrinsic pathway of the coagulation cascade. It binds to activated factor VIII, activates factor X, and ultimately leads to thrombin generation and fibrin clot formation, correcting the clotting defect in Hemophilia B.

The dose of Immunine is individualized. The prescribing clinician determines the amount and frequency based on the patient’s factor IX activity level, severity of bleeding, and clinical situation. No fixed regimen is provided here.

Safety data for Immunine in pregnancy and lactation are limited. Use is generally reserved for pregnant or nursing patients only when the potential benefit outweighs any possible risk, and decisions should be made by the treating physician.

To order Immunine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Immunine is a plasma‑derived factor IX concentrate similar in activity to other licensed factor IX products. Differences may lie in manufacturing processes, viral inactivation steps, and specific regulatory approvals. Clinical efficacy is comparable when appropriate dosing is applied.

Immunine must be stored at 2‑8 °C, protected from light, and should not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and potency.

Immunine is given by intravenous infusion. The infusion rate and volume are determined by the prescriber, and the product should be administered using aseptic technique in a clinical setting.

Serious risks include the development of inhibitory antibodies against factor IX, severe allergic reactions such as anaphylaxis, and rare thromboembolic events. Patients should be monitored closely for these complications during and after infusion.

Immunine should not be used in individuals with known hypersensitivity to human plasma‑derived proteins or any component of the formulation. Caution is also advised for patients with a history of severe allergic reactions or uncontrolled cardiovascular disease.